Targeting lung cancer: different approaches for different patients

Friday 17 April 2020, 13:00–14:00
Palexpo, Room A, Geneva, Switzerland

Faculty and agenda

Solang Peters (Chair)
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Extensive-stage SCLC: changing the paradigm with IO combinations

Johan Vansteenkiste
University Hospital KU Leuven, Leuven, Belgium
Unresectable stage III NSCLC: clinical implementation of new approaches

David Planchard
Institut Gustave Roussy, Villejuif, France
EGFRm NSCLC: targeted treatment options to improve outcomes in first-line locally advanced or mNSCLC and beyond progression

Audience Q&A

Refreshments are available prior to the symposium

AstraZeneca's commitment to sustainability

$19 million invested in environmental efficiency projects (NRRGG Fund)
CPD A Lists one of six companies worldwide to achieve double A listing for Climate Change and Water Security for three consecutive years
61% of our power is sourced or generated from renewable sources
100% of API (Active Pharmaceutical Ingredient) discharges from sites were safe
8% reduction in our water use since 2015
7% of our fleet of vehicles in Europe, North America and Japan is hybrid, plug-in or electric, up from <1% in 2017

AstraZeneca is investing up to $1 billion in a commitment to become carbon neutral by 2025 and carbon negative by 2030. Find out more about AstraZeneca’s Commitment to Sustainability at our website